Mar 2026 (Q1 FY26) — Apr 30, 2026
Indivior Pharmaceuticals Q1 FY26 — Strong SUBLOCADE Growth Drives Raised Full-Year Guidance
Read the full callIndivior Pharmaceuticals (INDV) earnings
- Jun 2026
- Mar 2026 (Q1 FY26)
- Dec 2025
Indivior Pharmaceuticals earnings: last reported Thu, 30 Apr 2026, for the quarter ended Mar 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 343 | +13.6% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 46.6 | +22.8 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 122 | +577.8% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$33.62 −1.58% · −$0.54
Performance +37.0% 1Y
1Y: $24.54 on 14 Oct 2025 → $33.62. High $41.83 (26 Jun 2026), low $24.09 (21 Oct 2025).
- Previous close
- $34.16
- 52-week range
- $24.09 – $41.83
- One year
- +33.47%
Overview
- Symbol
- INDV
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Dec 2025 (Q4 FY25) — Feb 26, 2026
Indivior Q4 FY25 — SUBLOCADE Momentum and Strong 2026 Outlook
Read the full callEvery analysed call
Indivior Pharmaceuticals earnings calls (INDV)
Financials
What the filings say
Net profit, year on year: +578% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 307 | 298 | 266 | 302 | 314 | 357 | 317 | 343 |
| Operating profit | 35 | 46 | 66 | 72 | 43 | 81 | 137 | 160 |
| Operating margin | 11.4% | 15.4% | 24.8% | 23.8% | 13.7% | 22.7% | 43.2% | 46.6% |
| Interest | 11 | 12 | 12 | 15 | 12 | 6 | 7 | 2 |
| Profit before tax | 30 | 38 | 59 | 62 | 37 | 81 | 115 | 160 |
| Tax rate | 26.7% | 44.7% | 18.6% | 71.0% | −13.5% | −25.9% | 22.6% | 23.8% |
| Net profit | 22 | 21 | 47 | 18 | 42 | 103 | 89 | 122 |
| EPS ($ per share) | 0.16 | — | 0.38 | 0.15 | 0.34 | — | 0.71 | 1.02 |
| Line item | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Equity capital | — | 68 | 62 | 62 |
| Reserves | — | -288 | -443 | -243 |
| Total liabilities | — | 1,942 | 1,652 | 1,300 |
| Fixed assets | — | 84 | 100 | 144 |
| Investments | — | 94 | 1 | 0 |
| Total assets | — | 1,758 | 1,316 | 1,201 |
| Line item | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Cash from operations | -4 | -300 | 36 | -27 |
| Cash from investing | -222 | -95 | 69 | -66 |
| Cash from financing | -101 | -64 | -102 | -30 |
| Capital expenditure | -5 | -8 | -29 | -66 |
| Free cash flow | -9 | -308 | 7 | -93 |
INDV revenue by segment
| Segment | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|
| Reportable | 100% | 100% | 100% | 100% | 100% | 100% | +13.6% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Revenue by region
Q2 FY2026 · share of revenue
- US 175% ↑ 8 pt
- Non Us 13% ↓ 4 pt
As INDV cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
48 filings between Jan 5, 2026 and Aug 27, 2026.
Open market
decisions to buy or sellPurchases
$311.6K
10 purchases by 7 insiders
Sales
$2.83M
3 sales by 2 insiders
100% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 20
- Award — granted as compensation
- 7
- Option exercise — converted options into shares
- 8
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Heidbreder Christian | — | $1.47M | Jul 10, 2026 |
| Preblick Ryan | — | $1.36M | Jun 8, 2026 |
| Anderson Woodrow D | $108.0K | — | Aug 27, 2026 |
| Wheadon David E. | $62.7K | — | Jan 5, 2026 |
| Kingsley Stuart A | $30.0K | — | Mar 6, 2026 |
| Ryan Barbara | $28.7K | — | Mar 13, 2026 |
| Humphreys Keith | $27.4K | — | Jan 5, 2026 |
| Stejbach Mark | $27.4K | — | Jan 5, 2026 |
Latest filings (48)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 27, 2026 | Anderson Woodrow D Chief Accounting Officer | Purchase | 1,500 | $53.5K |
| Aug 5, 2026 | Anderson Woodrow D Chief Accounting Officer | Purchase | 1,500 | $54.4K |
| Jul 10, 2026 | Heidbreder Christian Chief Scientific Officer | Sale 10b5-1 plan | 18,586 | $764.6K |
| Jun 22, 2026 | Ciaffoni Joseph Chief Executive Officer | Option exercise | 1,266,903 | — |
| Jun 22, 2026 | Ciaffoni Joseph Chief Executive Officer | Tax withheld | 612,549 | $23.47M |
| Jun 11, 2026 | Heidbreder Christian Chief Scientific Officer | Sale 10b5-1 plan | 18,586 | $707.4K |
| Jun 8, 2026 | Preblick Ryan Chief Financial Officer | Sale 10b5-1 plan | 36,000 | $1.36M |
| May 13, 2026 | Stejbach Mark Director | Award | 6,518 | $0 |
| May 13, 2026 | Thompson Juliet Director | Award | 6,518 | $0 |
| May 13, 2026 | Wheadon David E. Director | Award | 10,430 | $0 |
| May 13, 2026 | NINIVAGGI DANIEL A Director | Award | 6,518 | $0 |
| May 13, 2026 | Humphreys Keith Director | Award | 6,518 | $0 |
| May 13, 2026 | Ryan Barbara Director | Award | 6,518 | $0 |
| May 13, 2026 | Kingsley Stuart A Director | Award | 6,518 | $0 |
| May 12, 2026 | Thompson Juliet Director | Tax withheld | 1,117 | $42.8K |
| Mar 14, 2026 | Preblick Ryan Chief Financial Officer | Option exercise | 6,302 | — |
| Mar 14, 2026 | Preblick Ryan Chief Financial Officer | Tax withheld | 2,843 | $88.4K |
| Mar 13, 2026 | Ryan Barbara Director | Purchase | 8 | $249 |
| Mar 9, 2026 | Ryan Barbara Director | Purchase | 31 | $1.0K |
| Mar 6, 2026 | Kingsley Stuart A Director | Purchase | 940 | $30.0K |
| Mar 3, 2026 | Anderson Woodrow D Chief Accounting Officer | Option exercise | 5,946 | — |
| Mar 3, 2026 | Heidbreder Christian Chief Scientific Officer | Tax withheld | 45,797 | $1.46M |
| Mar 3, 2026 | Burris Jeffrey W Chief Legal Officer | Option exercise | 79,893 | — |
| Mar 3, 2026 | Burris Jeffrey W Chief Legal Officer | Tax withheld | 36,032 | $1.15M |
| Mar 3, 2026 | Anderson Woodrow D Chief Accounting Officer | Option exercise | 18,364 | — |
| Mar 3, 2026 | Anderson Woodrow D Chief Accounting Officer | Tax withheld | 8,283 | $264.9K |
| Mar 3, 2026 | Anderson Woodrow D Chief Accounting Officer | Tax withheld | 2,682 | $85.8K |
| Mar 3, 2026 | Heidbreder Christian Chief Scientific Officer | Option exercise | 101,544 | — |
| Mar 3, 2026 | Preblick Ryan Chief Financial Officer | Tax withheld | 87,597 | $2.80M |
| Mar 3, 2026 | Preblick Ryan Chief Financial Officer | Option exercise | 86,949 | — |
| Feb 10, 2026 | Burris Jeffrey W Chief Legal Officer | Award | 26,897 | $0 |
| Feb 10, 2026 | Barry Patrick A Chief Commercial Officer | Award | 31,380 | $0 |
| Feb 10, 2026 | Anderson Woodrow D Chief Accounting Officer | Award | 6,903 | $0 |
| Feb 10, 2026 | Heidbreder Christian Chief Scientific Officer | Award | 33,622 | $0 |
| Feb 10, 2026 | Preblick Ryan Chief Financial Officer | Award | 37,358 | $0 |
| Feb 10, 2026 | Ciaffoni Joseph Chief Executive Officer | Award | 79,976 | $0 |
| Jan 26, 2026 | Kingsley Stuart A Director | Award | 3,722 | $0 |
| Jan 26, 2026 | Stejbach Mark Director | Award | 3,722 | $0 |
| Jan 26, 2026 | Thompson Juliet Director | Award | 3,722 | $0 |
| Jan 26, 2026 | Wheadon David E. Director | Award | 5,955 | $0 |
| Jan 26, 2026 | Ryan Barbara Director | Award | 3,722 | $0 |
| Jan 26, 2026 | Humphreys Keith Director | Award | 3,722 | $0 |
| Jan 26, 2026 | NINIVAGGI DANIEL A Director | Award | 3,722 | $0 |
| Jan 5, 2026 | Stejbach Mark Director | Purchase 10b5-1 plan | 775 | $27.4K |
| Jan 5, 2026 | Wheadon David E. Director | Purchase 10b5-1 plan | 1,771 | $62.7K |
| Jan 5, 2026 | Ryan Barbara Director | Purchase 10b5-1 plan | 775 | $27.4K |
| Jan 5, 2026 | Humphreys Keith Director | Purchase 10b5-1 plan | 775 | $27.4K |
| Jan 5, 2026 | NINIVAGGI DANIEL A Director | Purchase 10b5-1 plan | 775 | $27.4K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Indivior Pharmaceuticals, Inc.
Free account. Everything above stays public.
Write why you follow Indivior Pharmaceuticals, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading